Notícias e Atividades da Biomarin Pharmaceutical

Biomarin Pharmaceutical é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Biomarin Pharmaceutical é uma empresa listada sob o símbolo BMRN (US).

Veja o organograma con seus 29 executivos principais

Biografias mais buscadas da Biomarin Pharmaceutical

• Alexander Hardy, Chief Executive Officer and President
• Robert Hombach, Director
• Willard Dere, Director

Recentes movimentos de executivos em Biomarin Pharmaceutical

• Timothy Walbert, ingressou na Companhia como Director  (Notícia publicada em 26 de fevereiro de 2025).
• Hank Fuch, President of Worldwide Research & Development, irá se aposentar em 29 de set. de 2024  (Notícia publicada em 22 de agosto de 2024).
• Greg Friberg ingressará na Companhia como Excecutive Vice President, Chief Research and Development Officer em 30 de set. de 2024  (Notícia publicada em 22 de agosto de 2024).

Clique aqui para ver outras movimentos em Biomarin Pharmaceutical

Criar um alerta
para seguir os movimentos de executivos da Biomarin Pharmaceutical.

Biomarin Pharmaceutical possui 1.834 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Eli Lilly (Estados Unidos).

Popular M&A news in Farmacêutica

• Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).
• Clario adquiriu NRx Pharmaceuticals (publicado em 18 de março de 2025).
• Knight Therapeutics has announced the acquisition of Paladin Labs  (publicado em 12 de março de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals
• Seth Harrison - Chairman and Director da Braeburn Pharmaceuticals

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Biomarin Pharmaceutical

• BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET
• BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria
• BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clini
• BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA
• BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance
• BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors
• BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET
• BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court
• BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA
• BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024
• View more press releases Close

Redes sociais sobre Biomarin Pharmaceutical

• Biomarin Pharmaceutical na Wikipedia, Google News e Yahoo Finance
• Biomarin Pharmaceutical na LinkedIn, Twitter e YouTube